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INTRODUCTION
Budd-Chiari syndrome (BCS) is characterized by the
obstruction of the hepatic venous outflow tract which can
be at the level of the hepatic venules, hepatic veins
(HV), inferior vena cava (IVC) or a simultaneous HV/IVC
block.1 Obstruction due to cardiac or pericardial
diseases and sinusoidal obstruction syndrome (SOS)
are not considered as BCS.2
Mostly patients with BCS have an underlying
thrombophilic disorder, i.e. primary BCS. This can be
inherited as protein C, protein S, antithrombin III
deficiencies or factor V Leiden (FVL) mutation, or
acquired as mostly myeloproliferative disorders (MPD).3
Compression or invasion of venous structures due to an
external source, such as a neoplasm, results in
secondary BCS.4 Clinical manifestations of BCS vary
from asymptomatic to symptomatic; acute, subacute,
chronic or fulminant. Classical signs include abdominal
pain, ascites, and hepatomegaly.3 Other manifestations
include pedal edema, jaundice, splenomegaly, gastro-
intestinal bleeding and hepatic encephalopathy.5
There is a lack of evidence-based strategies regarding
the management of BCS in South Asia like those
mentioned in the EASL and AASLD practice guidelines.
Anticoagulation and thrombolysis is the first-line
treatment, followed by angioplasty/stenting for those
patients with short-length stenosis.6 Transjugular
intrahepatic portosystemic shunt (TIPS) is the next step,
while liver transplantation (LT) is the ultimate rescue
option.7 As there is a dearth of published literature from
Pakistan reporting the trends, clinical features and
outcome of this syndrome in our population, this study
was focused on these clinical aspects of BCS which will
enhance the understanding of the disease spectrum in
local population.
The aim of this study was to determine the clinical
characteristics of Budd-Chiari syndrome (BCS), its
causes and outcome at a tertiary care hospital.
METHODOLOGY
A retrospective analysis of data was conducted at the
Aga Khan University Hospital after permission was
obtained from the Ethical Review Committee. A
proforma was used for data collection which included
demographics, history and examination findings,
investigations, course and disease outcome. Medical
records of patients with BCS diagnosed on the basis of
imaging, admitted from 2004 to 2014, were obtained from
the Health Information Management Services (HIMS).
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ABSTRACT
Objective: To determine the clinical characteristics of Budd-Chiari syndrome (BCS), its causes and outcome at a tertiary
care hospital.
Study Design: An observational study.
Place and Duration of Study: The Aga Khan University Hospital, Karachi, from 2004 to 2014.
Methodology: A retrospective analysis of data was conducted. A predesigned questionnaire was filled from medical
records of patients with BCS. Clinical features, etiology, management and outcome was noted from 2004 to 2014.
Descriptive statistics were determined.
Results: Forty-five patients' charts were reviewed; 26 (57.8%) were male patients. The median (IQR) age at diagnosis
was 26.0 (20.5 to 34.5) years. Primary BCS was seen in 27 (60.0%) patients. The most frequent clinical features included
ascites (82.2%), abdominal pain (55.6%), and hepatomegaly (31.1%). A combined hepatic vein/inferior vena cava block
was found in 25 (55.6%) patients. Out of the 28 tested patients protein C and protein S deficiencies were detected in 22
(78.6%) and 17 (60.7%) patients, respectively.  Antithrombin III deficiency was detected in 14 (58.3%) of those tested patients.
Anticoagulants were used in 24 (53.3%) patients. TIPS was done in 11 (24.4%) patients. Mortality was 6.7% (n=3).
Conclusion: Congenital thrombophilia was a major causal factor. Age, clinical features, biochemistry and management
are important factors in survival.
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Patients diagnosed with other comorbid conditions such
as hypertension, diabetes mellitus and ischemic heart
disease were excluded from the study. Forty-five
patients' charts were reviewed for the study.
Continuous variables were described as mean ± standard
deviation (SD) or median (IQR), and categorical variables
were presented as a number (%). SPSS version 19 was
used to develop the frequency tables.
RESULTS
There were 26 (57.8%) male patients. The median IQR
(interquartile range) age at diagnosis was 26.0 (20.5 to
34.5) years.
Twenty-seven (60.0%) patients were classified as
primary BCS, while 3 (6.7%) patients were classified as
secondary BCS. The diagnosis of the type of BCS was
not confirmed in the remaining 15 (33.3%) patients.
Thirty-six (80.0%) patients presented with abdominal
distension, and 25 (55.6%) complained of abdominal
pain. On physical examination, 37 (82.2%) patients had
ascites and 20 (44.4%) had abdominal tenderness
(Table I).
Patients were classified as those with primary and
secondary BCS on the basis of the etiological workup
(Table II). Twenty-two (78.6%) and 17 (60.7%) out of the
28 tested patients had protein C and protein S
deficiencies, respectively. Out of the 24 patients who
were tested, 14 (58.3%) patients had antithrombin III
deficiency. Three (6.7%) patients had myeloproliferative
disorder. Three (6.7%) patients had webs in the IVC
resulting in obstruction. Out of the 3 patients with
secondary BCS, 2 had hepatocellular carcinoma (HCC).
Using imaging modalities including US Doppler and/or
CT angiography, 25 (55.6%) patients were seen to
have a combined HV/IVC block, 11 (24.4%) had an
isolated HV block, and 3 (6.7%) had an isolated IVC
block. Venous collaterals were present in 11 (24.4%)
patients. Caudate lobe hypertrophy was reported in 18
(40%) patients, hepatomegaly was seen in 27 (60%)
patients and splenomegaly in 20 (44.4%) patients.
Esophagogastroduodenoscopy (EGD) was performed in
28 (62.2%) patients, while 22 (48.8%) patients were
reported to have esophageal varices.
Out of 45 patients, 42 (93.3%) survived. Of these, 30
(66.7%) patients had a chronic course. The course and
outcome of the disease has been summarized in
Table III. Death was the outcome in 3 (6.7%) patients. Of
these, 2 (4.4%) had an acute course and died as a result
of septic shock, and 1 (2.2%) developed hepatic
encephalopathy, followed by heart failure, after a chronic
course.
For management, antiplatelet agents (Aspirin 75 mg/
Clopidogrel 75mg) were given to 5 (11.1%) patients;
anticoagulants were used in 24 (53.3%) patients and
thrombolytic therapy in 1 (2.2%) patient. For symptomatic
therapy, proton-pump inhibitors were used in 34 (75.6%)
patients, diuretics in 27 (60.0%) patients and antiemetic
agents in 28 (62.2%) patients. Angioplasty/stenting was
done in 5 (11.1%) patients. Eleven (24.4%) patients
underwent TIPS; mesocaval shunt was done in 1 (2.2%)
patient after TIPS failure. No liver transplants were done
in our setting, but patients were referred to other places
for getting a liver transplant.
DISCUSSION
BCS has been seen to vary epidemiologically from one
place to another. In a study from Western India, the
highest prevalence was seen during the ages of 21-40
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Table I: Clinical features of BCS.
Clinical features n=45 Percentage of n (%)
Male patients 26 57.8
Female patients 19 42.2
Ascites 37 82.2
Abd. distension 36 80.0
Abd. pain 25 55.6
Jaundice 25 55.6
Abd. tenderness 20 44.4
Pedal edema 18 40.0
Hepatomegaly 14 31.1
Splenomegaly 10 22.2
GI bleeding 8 17.8
Spider nevi 6 13.3
Fever 5 11.1
Encephalopathy 2 4.4
Table II: Etiology of BCS. 
Etiological factor Patients  Patients  Percentage 
tested/ w/positive (%)
accounted for etiology
Protein C deficiency 28 22 78.6
Protein S deficiency 28 17 60.7
Antithrombin III deficiency 24 14 58.3
Factor V Leiden mutation 17 5 29.4
Postpartum period 19 3 15.8
Myeloproliferative disorder 45 3 6.7
Hyperhomocysteinemia 45 3 6.7
MOVC 45 3 6.7
HCC 45 2 4.4
Antiphospholipid syndrome 31 1 3.2
Prothrombin gene mutation 45 1 2.2
PNH 45 1 2.2
Hydatid cyst disease 45 1 2.2
MOVC = Membravous obstruction of veva cava;   HCC = Hepatocellular carcinona;
PNH = Paroxysmal nocturnal hemoglobinuria.
Table III: Course and outcome of BCS.
Course of BCS n=45 Percentage (%)





Inpatients who died 3 6.7
Acute 2 4.4
Chronic 1 2.2
years, with women contributing towards most of the
cases falling between ages 31-40 years.8 Plessier and
Valla have mentioned in their article, in 2008, that men
show a higher prevalence in Asia; whereas in western
countries, women have taken the lead.2 In this study,
there were more men than women. However, this could
be due to the patriarchal society of Pakistan, where
female health issues are underreported.
Most of the patients with BCS present with ascites,
abdominal pain, and hepatomegaly.9 Ascites has been
seen as the most common symptom, being present in
more than 80% of the patients in one study from India
and in another from Pennsylvania.10,11 Such was also
the case in this study.
Chronic presentation is the most common among BCS
patients.5 In a study from Turkey, more than half of the
patients had the chronic form, while the acute and
subacute forms had much lower representation.12
Similarly, in this study, the most common presentation
was a chronic course.
BCS has been classified as primary or secondary. In a
study including 115 patients, from Algeria, primary BCS
was reported in 109 (94.7%) patients and secondary
BCS was reported in 6 (5.3%) patients.13 This is similar
to the present study, which also showed a predominance
of primary BCS.
Different prothrombotic conditions have been described
as etiological factors for primary BCS. Congenital
thrombophilia is more common etiology in western
countries.5 However, there have been studies from the
East which showed hereditary deficiencies as the major
cause of BCS. In a study from Western India, FVL
mutation was seen as the most common state of
hereditary thrombophilia and antithrombin III deficiency
as the least common.8 In another study, protein C
deficiency has been seen as the most common cause
among congenital hypercoaguable states, resulting in
BCS.14 In this study, protein C deficiency was the
most common hereditary predisposing condition to
thrombosis as well, followed by Protein S and
antithrombin III deficiencies. However, some of these
deficiencies could have been a result of chronic liver
disease. PT value helps evaluate whether this is truly an
inherited deficiency or not. The median value (IQR) of
PT was 15.9 (13.4 to 21.0) seconds. Twenty-nine
(14.5%) patients had a higher than normal value for PT.
A positive family history for these deficiencies also helps
confirm their hereditary nature,15 but accounting for data
from relatives was not quite economical in the study
setting.
Membranous obstruction of the IVC (MOVC) has been
described as the major cause of BCS in eastern
countries.5,12 In this study, only 3 (6.7%) patients had
webs in the IVC causing obstruction.
Generally, MPD are known to be the most common
cause of BCS, with polycythemia vera (PV) occurring
with the highest frequency and accounting for 10-40%
cases of BCS.16 Previous studies have had results
which described MPD as the predominant causal factor,
being present in 70%, and 34% of the patients in two
different studies.13,17 However, among our patients, the
prevalence of MPD was quite low, with only 3 (6.7%)
patients representing cases secondary to PV. The
detection of JAK2 V617F mutation helps make the
diagnosis of MPD.18 Two patients in this series with PV
tested positive for this mutation.
Pregnancy is one of the precipitating factors of BCS,
especially in eastern countries.19 In this study, 3 (15.8%)
female patients were seen to have pregnancy as one of
the potential causal factors of BCS. FVL mutation has
been observed to be present in most of the cases
associated with pregnancy.16,17 In this study, 1 of the 3
women having a history of recent pregnancy also tested
positive for the FVL mutation. However, she was not
classified as primary BCS, because on CT scan, she
was seen to have a cyst in segment VIII of the right lobe
of her liver which was resulting in direct compression of
the IVC. She was confirmed as a case of hydatid cyst
disease, and therefore, classified as a case of
secondary BCS. In one study, from Turkey, hydatid cyst
disease was the second highest cause of BCS among
all the patients.12
Isolated hepatic vein obstruction has been described as
the most common anatomy in BCS, followed by a
combined HV and IVC obstruction. Isolated IVC
obstruction is relatively low.12 This study also described
isolated IVC obstruction as the least common type of
obstruction. However, a combined obstruction of HV and
IVC was the most common type seen in this study,
followed by isolated HV obstruction.
Most of these patients survived the disease with death
being the outcome in 3 (6.7%) patients. This is a much
lower number than that reported in other studies with
death rates as high as 21.3% and 27.0%, respectively.6,11
This study is limited to its small sample size and retro-
spective nature. Also, because of financial constraints,
not all patients were tested for all the etiological factors.
Hence, further research is required to fully encompass
the understanding of this disease and its management.
CONCLUSION
This study has elucidated features regarding the clinical
aspects and course of BCS, which will be conducive to
wise decision-making regarding the management of this
condition.
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